TABLE 1.
KDM2A expression and clinicopathological characteristics of breast cancer tissues
| Breast carcinoma subtype | KDM2A scorea | No. of specimens resected | No. of specimens with: |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strong KDM2A expression in invading cellsb | HER2 expression level of: |
ERc |
PRc |
TNBCsd |
||||||||
| 0 | 1 | 2 | 3 | − | + | − | + | |||||
| Papillotubular | 4 | 2 | 2 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 2 | 0 |
| 5 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | |
| 6 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | |
| 7 | 5 | 3 | 1 | 0 | 0 | 4 | 3 | 2 | 5 | 0 | 1 | |
| 8 | 9 | 3 | 5 | 4 | 0 | 0 | 1 | 8 | 1 | 8 | 1 | |
| Solid-tubular | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | |
| 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 7 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Scirrhous | 4 | 2 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 0 |
| 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 6 | 4 | 2 | 3 | 0 | 1 | 0 | 0 | 4 | 1 | 3 | 0 | |
| 7 | 3 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | |
| 8 | 5 | 0 | 3 | 1 | 1 | 0 | 0 | 5 | 0 | 5 | 0 | |
| Mucinous | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 7 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Micropapillary | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | |
| 6 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | |
| 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
a
The ratio of stained cells (0 to 5) was added to the strength of the KDM2A staining (0 to 3) to produce the KDM2A score (0 to 8). The KDM2A scores of all specimens ranged from 4 to 8.
b
KDM2A staining intensity score of 3 in breast cancer cells invading around the main tumor.
c
+, present; −, absent.
d
TNBCs, triple-negative breast cancers, i.e., tumors that do not express estrogen receptor (ER) or progesterone receptor (PR) and do not have HER-2/Neu amplification.